PET microdose study of donepezi in humans

PET microdose study of donepezi in humans - Donepezil PET

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004786

Enrollment

Registered

2010-12-24

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

normal volunteer

Interventions

To analyze pharmacokinetics of C-11 donepezil after 1mg (n=6) oral administration. The study period is from January to March 2022. To analyze pharmacokinetics of C-11 donepezil after 3mg (n=6) oral ad

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: normal volunteer

Exclusion criteria

Exclusion criteria: liver dysfunction, ECG abnormality, past history of gastric ulcer, symptoms of extrapyramidal systems, intake of other drugs, pregnant,

Design outcomes

Primary

Measure	Time frame
radioactivity of donpezil in the brain	—

Secondary

Measure	Time frame
sequential changes in donepezil radioactivity in the brain by 60minafter administration	—

Countries

Japan

Contacts

Public ContactJun Hatazawa

Osaka University Hospital Nuclear Medicine

hatazawa@tracer.med.osaka-u.ac.jp81-6-6879-3461

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026